Copyright
©The Author(s) 2018.
World J Gastrointest Oncol. Dec 15, 2018; 10(12): 505-515
Published online Dec 15, 2018. doi: 10.4251/wjgo.v10.i12.505
Published online Dec 15, 2018. doi: 10.4251/wjgo.v10.i12.505
Table 4 Clinical trials of second-line treatment for gemcitabine pre-treated unresectable pancreatic cancer
Author (yr) | Type of study | Regimen | Patients, n | KPS ≥ 90 or ECOG ≤ 1, % | MPC, % | ORR, % | DCR, % | PFS/TTP, mo | OS, mo |
Yoo et al[15] 2009 | II | Modified FOLFOX | 30 | 97 | 100 | 7 | 17 | 6.0 wk | 14.9 wk |
Modified FOLFIRI.3 | 31 | 100 | 100 | 0 | 23 | 8.3 wk | 16.6 wk | ||
Novarino et al[14] 2009 | II | Oxaliplatin/5-FU/LV | 23 | 73.9 | 69.6 | 0 | 23.5 | 11.6 wk1 | 17.1 wk |
Pelzer et al[5] 2011 | III | BSC | 23 | 52.2 | 69.6 | 0 | NA | NA | 2.3 |
Oxaliplatin/5-FU/LV (OFF) | 23 | 47.8 | 73.9 | 0 | NA | NA | 4.8 (P = 0.008) | ||
Chung et al[23] 2013 | II | FOLFOX4 | 44 | NA | 100 | 11.4 | 40.9 | 9.9 wk1 | 31.1 wk |
Oettle et al[6] 2014 | III | 5-FU/LV (FF) | 84 | 47.6 | 88.1 | NA | NA | 2 | 3.3 |
Oxaliplatin/5-FU/LV (OFF) | 84 | 53.9 | 88.2 | NA | NA | 2.9 (P = 0.019) | 5.9 (P = 0.01) | ||
Zaanan et al[17] 2014 | Prospective cohort | FOLFOX2 | 27 | 44.4 | 100 | 0 | 36.4 | 1.7 | 4.3 |
Wang-Gillam et al[7] 2016 | III | 5-FU/LV | 119 | 48 | 100 | 1 | NA | 1.5 | 4.2 |
Nal-IRI/5-FU/LV | 117 | 59 | 100 | 16 | NA | 3.1 (P < 0.001) | 6.1 (P = 0.01) | ||
Nal-IRI | 151 | 57 | 100 | 6 | NA | 2.7 (P = 0.1) | 4.9 (P = 0.94) | ||
Gill et al[24] 2016 | III | Modified FOLFOX6 | 54 | 88.9 | 92.6 | 13.2 | 44.7 | 3.1 | 6.1 |
Infusional 5FU/LV | 54 | 94.3 | 94.4 | 8.5 (P = 0.36) | 55.3 | 2.9 (P = 0.99) | 9.9 (P = 0.02) | ||
Present study | II | FOLFIRINOX with RIO | 48 (MPC: 38) | 95.8 | 79.2 | 18.8 (MPC: 23.7) | 62.5 (MPC: 57.9) | 5.8 (MPC: 5.4) | 9 (MPC: 8.4) |
- Citation: Chung MJ, Kang H, Kim HG, Hyun JJ, Lee JK, Lee KH, Noh MH, Kang DH, Lee SH, Bang S, Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. World J Gastrointest Oncol 2018; 10(12): 505-515
- URL: https://www.wjgnet.com/1948-5204/full/v10/i12/505.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v10.i12.505